Abstract
Bone loss in rheumatic disorders is multifactorial. Contributing factors are the inflammatory process per se including inflammatory cytokines, traditional clinical risk factors and drugs with glucocorticoids being the leading cause. Furthermore, autoimmune rheumatic diseases affect women of childbearing age and young men, who may not have attained peak bone mass at the time of diagnosis. As rheumatologists we need to be mindful of these factors and optimise bone health by addressing modifiable factors and timely implement primary prevention.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Consensus A (1993) Consensus development conference: diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 94:646–650
Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R, National Osteoporosis Foundation (2014) Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 25(10):2359–2381
Wright NC, Saag KG, Dawson-Hughes B, Khosla S, Siris ES (2017) The impact of the new National Bone Health Alliance (NBHA) diagnostic criteria on the prevalence of osteoporosis in the USA. Osteoporos Int 28(4):1225–1232
Löfman O, Larsson L, Toss G (2000) Bone mineral density in diagnosis of osteoporosis: reference population, definition of peak bone mass, and measured site determine prevalence. J Clin Densitom 3(2):177–186
Jung Y-K, Kang Y-M, Han S (2019) Osteoclasts in the inflammatory arthritis: implications for pathologic osteolysis. Immune Netw 19(1):e2
Amarasekera DS, Yu J, Rho J (2015) Bone loss triggered by the cytokine network in inflammatory autoimmune diseases. J Immunol Res 2015:832127
Coury F, Peyruchard O, Machuca-Gayet I (2019) Osteoimmunology of bone loss in inflammatory rheumatic disease. Front Immunol 10:679
Liu J, Curtis EM, Cooper C, Harvey NC (2019) State of the art in osteoporosis risk assessment and treatment. J Endocrinol Investig 42:1149–1164
Iseme RA, Mcevoy M, Kelly B, Agnew L, Walker FR (2017) Is osteoporosis an immune mediated disorder? Bone Rep 7:121–131
Briot K, Geusens P, Em Bultink I, Lems WF, Roux C (2017) Inflammatory diseases and bone fragility. Osteoporos Int 28:3301–3314
LUPUS UK (2015) Diet and exercise. Available from: https://www.lupusuk.org.uk/diet-and-exercise/. Accessed 3 May 2019
Molto A, Nikiphorou E (2018) Comorbidities in spondyloarthritis. Front Med 5:62
Valenzuela A, Baron M, Canadian Scleroderma Research Group, Herrick AL, Proudman S, Stevens W, Australian Scleroderma Interest Group, Rodriguez-Reyna TS, Vacca A, Medsger TA Jr, Hinchcliff M, Hsu V, Wu JY, Fiorentino D, Chung L (2016) Calcinosis is associated with digital ulcers and osteoporosis in patients with systemic sclerosis: a Scleroderma Clinical Trials Consortium Study. Semin Arthritis Rheum 46(3):344–349
Sheu A, Diamond T (2016) Secondary osteoporosis. Aust Prescr 39(3):85–87
Lane NE (2019) Glucocorticoid-induced osteoporosis: new insights into the pathophysiology and treatments. Curr Osteoporos Rep 17(1):1–7
Hsu E, Nanes M (2017) Advances in treatment of glucocorticoid-induced osteoporosis. Curr Opin Endocrinol Diab Obes 24(6):411–417
Compston J (2018) Glucocorticoid-induced osteoporosis: and update. Endocrine 61:7–16
Balasubramanian A, Wade SW, Adler RA, Saag K, Pannacciulli N, Curtis JR (2018) Glucocorticoid exposure and fracture risk in a cohort of US patients with selected conditions. J Bone Miner Res 33(10):1881–1888
National Institute for Health and Care Excellence (NICE) (2012) Osteoporosis: assessing the risk of a fragility fracture: clinical guideline [CG146]. Available from: https://www.nice.org.uk/guidance/cg146. Accessed 15 May 2019
Centre for Metabolic Bone Diseases, University of Sheffield, UK. FRAX: fracture risk assessment tool. Available from: https://www.sheffield.ac.uk/FRAX/tool.aspx. Accessed 20 May 2019
Kanis JA, Harvey NC, Johansson H, Oden A, McCloskey EV, Leslie WD (2017) Overview of fracture prediction tools. J Clin Densitom 20(3):444–450
Kanis JA, Glüer CC (2000) An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos Int 11(3):192–202
Crandall CJ, Newberry SJ, Diamant A, Lim YW, Gellad WF, Booth MJ, Motala A, Shekelle PG (2014) Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Ann Intern Med 161(10):711–723
Patrick AR, Brookhart MA, Losina E, Schousboe JT, Cadarette SM, Mogun H, Solomon DH (2010) The complex relation between bisphosphonate adherence and fracture reduction. J Clin Endocrinol Metab 95(7):3251–3259
Yates J (2013) A meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women. Osteoporos Int 24(1):253–262
Lems WF, Raterman H (2017) Critical issues and current challenges in osteoporosis and fracture prevention. An overview of unmet needs. Therap Adv Musculoskel Dis 9:299–316
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Godsave, C., Garner, R., Pande, I. (2020). Osteoporosis in Autoimmune Rheumatic Diseases. In: Sharma, S. (eds) Women's Health in Autoimmune Diseases. Springer, Singapore. https://doi.org/10.1007/978-981-15-0114-2_24
Download citation
DOI: https://doi.org/10.1007/978-981-15-0114-2_24
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-0113-5
Online ISBN: 978-981-15-0114-2
eBook Packages: MedicineMedicine (R0)